Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

Continuous cultures of fused cells secreting antibody of predefined specificity

Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200 · see citing works

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

Colombel, J., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A. A., Rachmilewitz, D., Lichtiger, S., D’Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,140 · see citing works

Replacing the complementarity-determining regions in a human antibody with those from a mouse

Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406 · see citing works

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,040 · see citing works

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P. J., Katsikis, P. D., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361206 · Cited by 1,038 · see citing works

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 784 · see citing works

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Fürst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., Benedetti, F. D., Dorner, T. E., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 691 · see citing works

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

Vermeire, S., Noman, M., Assche, G. V., Baert, F., D’Haens, G., & Rutgeerts, P. (2007) · Gut · doi:10.1136/gut.2006.099978 · Cited by 602 · see citing works

PEGylated antibodies and antibody fragments for improved therapy: a review

Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 558 · see citing works

Immunogenicity of therapeutic proteins: Clinical implications and future prospects

Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 557 · see citing works

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

Brekke, O. H., & Sandlie, I. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 552 · see citing works

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial

Farrell, R. J., Alsahli, M., Jeen, Y.-T., Falchuk, K. R., Peppercorn, M. A., & Michetti, P. (2003) · Gastroenterology · doi:10.1053/gast.2003.50145 · Cited by 550 · see citing works

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S., Miranda, P. C., Pazdur, J., Bae, S.-C., PALMER, W. R., Zrubek, J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099010 · Cited by 540 · see citing works

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Steenholdt, C., Brynskov, J., Thomsen, O. Ø., Munck, L. K., Fallingborg, J., Christensen, L. A., Pedersen, G., Kjeldsen, J., Jacobsen, B. A., Oxholm, A. S., et al. (2013) · Gut · doi:10.1136/gutjnl-2013-305279 · Cited by 459 · see citing works

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

van Schouwenburg, P. A., Rispens, T., & Wolbink, G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 441 · see citing works

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

Garcês, S., Demengeot, J., & Benito‐Garcia, E. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202220 · Cited by 411 · see citing works

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., & Saxne, T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22214 · Cited by 383 · see citing works

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Xavier Mariette, A., & Marcelli, C. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356 · see citing works

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Allez, M., Κarmiris, K., Louis, E. J., Assche, G. V., Ben‐Horin, S., Klein, A., van der Woude, J., Baert, F., Eliakim, R., Katsanos, K. H., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2010.04.004 · Cited by 335 · see citing works

Factors influencing the immunogenicity of therapeutic proteins

Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332 · see citing works

Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Keystone, E. C., Schiff, M. H., Kremer, J. M., Kafka, S. P., Lovy, M. R., DeVries, T. A., & Burge, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20019 · Cited by 284 · see citing works

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

Gupta, S., Indelicato, S. R., Jethwa, V., Kawabata, T. T., Kelley, M. M., Mire‐Sluis, A. R., Richards, S. M., Rup, B. J., Shores, E. W., Swanson, S. J., et al. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.12.004 · Cited by 242 · see citing works

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

Wolbink, G., Voskuyl, A. E., Lems, W. F., de Groot, E. R., Nurmohamed, M. T., Tak, P. P., Dijkmans, B. A. C., & Aarden, L. A. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030452 · Cited by 215 · see citing works

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement.

Aarden, L., Ruuls, S., & Wolbink, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.011 · Cited by 198 · see citing works

Immunogenicity and autoimmunity during anti-TNF therapy

Atzeni, F., Talotta, R., Salaffi, F., Cassinotti, A., Varisco, V., Battellino, M., Ardizzone, S., Pace, F., & Sarzi‐Puttini, P. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.10.021 · Cited by 196 · see citing works

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A., Porawska, W., Box, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30463 · Cited by 196 · see citing works

Dealing with immunogenicity of biologicals: assessment and clinical relevance

Wolbink, G., Aarden, L. A., & Dijkmans, B. A. C. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328329ed8b · Cited by 183 · see citing works

Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases

Aikawa, N. E., de Carvalho, J. F., Silva, C. A., & Bonfá, E. (2009) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-009-8140-3 · Cited by 179 · see citing works

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

Jamnitski, A., Bartelds, G. M., Nurmohamed, M. T., van Schouwenburg, P. A., van Schaardenburg, D., Stapel, S. O., Dijkmans, B. A. C., Aarden, L. A., & Wolbink, G. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135111 · Cited by 179 · see citing works

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

van Schouwenburg, P. A., Bartelds, G. M., Hart, M. H. L., Aarden, L. A., Wolbink, G., & Wouters, D. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.09.005 · Cited by 163 · see citing works

Differential effect of drug interference in immunogenicity assays

Hart, M. H. L., de Vrieze, H., Wouters, D., Wolbink, G., Killestein, J., de Groot, E. R., Aarden, L. A., & Rispens, T. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.07.019 · Cited by 160 · see citing works

Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials

Rau, R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii70 · Cited by 158 · see citing works

Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions

Maneiro, J. R., Salgado, E., & Gómez-Reino, J. J. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.7430 · Cited by 152 · see citing works

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

Bendtzen, K., Ainsworth, M. A., Steenholdt, C., Thomsen, O. Ø., & Brynskov, J. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802699278 · Cited by 143 · see citing works

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012

Furst, D., Keystone, E., So, A., Braun, J., Breedveld, F., Burmester, G., de Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203348 · Cited by 141 · see citing works

Current Immunotherapy in Rheumatoid Arthritis

Meier, F. M. P., Frerix, M., Hermann, W., & Müller‐Ladner, U. (2013) · Immunotherapy · doi:10.2217/imt.13.94 · Cited by 127 · see citing works

2012 Brazilian Society Of Rheumatology Consensus For The Treatment Of Rheumatoid Arthritis

da Mota, L. M. H., Cruz, B. A., Brenol, C. V., Pereira, I. A., Rezende-Fronza, L. S., Bertolo, M. B., de Freitas, M. V. C., Silva, N. A., Louzada‐Júnior, P., Giorgi, R. D. N., et al. (2012) · Americanae (AECID Library) · Cited by 124 · see citing works

Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease

Steenholdt, C., Ainsworth, M. A., Tovey, M. G., Klausen, T. W., Thomsen, O. Ø., Brynskov, J., & Bendtzen, K. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31828d23c3 · Cited by 115 · see citing works

Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide

da Mota, L. M. H., Cruz, B. A., Brenol, C. V., Pereira, I. A., Rezende-Fronza, L. S., Bértolo, M. B., Freitas, M. V. C., da Silva, N. A., Louzada‐Júnior, P., Giorgi, R. D. N., et al. (2012) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042012000200002 · Cited by 103 · see citing works

Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists

Lallemand, C., Kavrochorianou, N., Steenholdt, C., Bendtzen, K., Ainsworth, M. A., Méritet, J., Blanchard, B., Lebon, P., Taylor, P. C., Charles, P. J., et al. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.08.022 · Cited by 99 · see citing works

Binding Characteristics of Tumor Necrosis Factor Receptor-Fc Fusion Proteins vs Anti-Tumor Necrosis Factor mAbs

Kohno, T., Tam, L. T., Stevens, S. R., & Louie, J. S. (2007) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650034 · Cited by 91 · see citing works

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies

Garcês, S., Antunes, M. C. D. S., Benito‐Garcia, E., da Silva, J. C., Aarden, L. A., & Demengeot, J. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203296 · Cited by 87 · see citing works

Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment

Emery, P. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes115 · Cited by 83 · see citing works

Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection

Bendtzen, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00109 · Cited by 73 · see citing works

Comparison of long‐term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

Krieckaert, C. L. M., Jamnitski, A., Nurmohamed, M. T., Kostense, P. J., Boers, M., & Wolbink, G. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34680 · Cited by 67 · see citing works

Comparative Analyses of Complex Formation and Binding Sites between Human Tumor Necrosis Factor-alpha and its Three Antagonists Elucidate their Different Neutralizing Mechanisms

Kim, M.-S., Lee, S., Song, M.-Y., Yoo, T. H., Lee, B.-K., & Kim, Y. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.10.034 · Cited by 66 · see citing works

Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics

Xue, L., & Rup, B. J. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9497-z · Cited by 63 · see citing works

Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics

Tatarewicz, S. M., Miller, J. M., Swanson, S. J., & Moxness, M. S. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.03.012 · Cited by 61 · see citing works

Enhanced Absorption of Insulin and (Asu1,7)Eel‐Calcitonin using Novel Azopolymer‐Coated Pellets for Colon‐Specific Drug Delivery

Tozaki, H., Nishioka, J., Komoike, J., Okada, N., Fujita, T., Muranishi, S., Kim, S., Terashima, H., & Yamamoto, A. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200101)90:1 · Cited by 59 · see citing works

Anti-TNF-α Biotherapies: Perspectives for Evidence-Based Personalized Medicine

Bendtzen, K. (2012) · Immunotherapy · doi:10.2217/imt.12.114 · Cited by 55 · see citing works

Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists.

Bendtzen, K. (2013) · PubMed · Cited by 53 · see citing works

The Complex Clinical Picture of Side Effects to Biologicals

Hausmann, O. V., Seitz, M., Villiger, P. M., & Pichler, W. J. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.03.001 · Cited by 49 · see citing works

Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases

Borchers, A. T., Leibushor, N., Cheema, G. S., Naguwa, S. M., & Gershwin, M. E. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.08.002 · Cited by 48 · see citing works

Tumor necrosis factor as a pharmacological target

Ghezzi, P., & Cerami, A. (2005) · Molecular Biotechnology · doi:10.1385/mb:31:3:239 · Cited by 45 · see citing works

Is there a need for immunopharmacologic guidance of anti–tumor necrosis factor therapies?

Bendtzen, K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30207 · Cited by 43 · see citing works

Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence

Bendtzen, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00152 · Cited by 32 · see citing works

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

van der Maas, A., van den Bemt, B. J. F., Wolbink, G., van den Hoogen, F. H. J., van Riel, P. L. C. M., & den Broeder, A. A. (2012) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-13-184 · Cited by 29 · see citing works

Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases.

Spinelli, F. R., & Valesini, G. (2014) · PubMed · Cited by 27 · see citing works

Biological Therapies for Rheumatoid Arthritis: Progress to Date

Malviya, G., Salemi, S., Laganà, B., Diamanti, A., D'Amelio, R., & Signore, A. (2013) · BioDrugs · doi:10.1007/s40259-013-0021-x · Cited by 24 · see citing works

Revolutionary Change in Rheumatoid Arthritis Managementwith Biological Therapy

Takeuchi, T. (2011) · The Keio Journal of Medicine · doi:10.2302/kjm.60.75 · Cited by 23 · see citing works

Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis

Casteele, N. V., & Khanna, R. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2150-2 · Cited by 15 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

Khanna, D., Allanore, Y., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Pope, J. E., Atsumi, T., Bečvář, R., Czirják, L., HACHULLA, E., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216823 · Cited by 111 · see citing works

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies

Scuteri, D., Adornetto, A., Rombolà, L., Naturale, M. D., Morrone, L. A., Bagetta, G., Tonin, P., & Corasaniti, M. T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00363 · Cited by 74 · see citing works

Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search

Roodenrijs, N. M. T., Welsing, P. M. J., van Roon, J. A. G., Schoneveld, J. L. M., van der Goes, M. C., Nagy, G., Townsend, M. J., & van Laar, J. M. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac114 · Cited by 64 · see citing works

A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis

Wong, D. J., Park, D., Park, S. J., Haller, C. A., Chen, J., Dai, E., Liu, L., Mandhapati, A. R., Eradi, P., Dhakal, B., et al. (2021) · Blood · doi:10.1182/blood.2020009428 · Cited by 53 · see citing works

Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis

Khoo, J. K., Barnes, H., Key, S., Glaspole, I., & Östör, A. J. K. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa117 · Cited by 50 · see citing works

First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

Banfield, C. R., Rudin, D., Bhattacharya, I., Goteti, K., Li, G., Hassan‐Zahraee, M., Brown, L. S., Hung, K. E., Pawlak, S., & Lepsy, C. S. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14187 · Cited by 35 · see citing works

Next-generation bNAbs for HIV-1 cure strategies

Schriek, A. I., Aldon, Y., van Gils, M. J., & de Taeye, S. W. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105788 · Cited by 27 · see citing works

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease

Reinisch, W., Gecse, K. B., Halfvarson, J., Irving, P. M., Jahnsen, J., Peyrin‐Biroulet, L., Rogler, G., Schreiber, S., & Danese, S. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa078 · Cited by 28 · see citing works

Rheumatoid arthritis molecular targets and their importance to flavonoid‐based therapy

Rufino, A. T., Freitas, M., Proença, C., de Oliveira, J. M. P. F., Fernandes, E. G. R., & Ribeiro, D. (2023) · Medicinal Research Reviews · doi:10.1002/med.21990 · Cited by 28 · see citing works

Site-selective oral delivery of therapeutic antibodies to the inflamed colon via a folic acid-grafted organic/inorganic hybrid nanocomposite system

Lee, S. H., Song, J. G., & Han, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.006 · Cited by 27 · see citing works

Advances in biosynthesis of peptide drugs: Technology and industrialization

Wang, J., Chen, L., Qin, S., Xie, M., Luo, S., & Li, W. (2023) · Biotechnology Journal · doi:10.1002/biot.202300256 · Cited by 25 · see citing works

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Rodríguez-Alcolado, L., Grueso-Navarro, E., Arias, Á., Lucendo, A. J., & Mendieta, E. J. L. (2024) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjae006 · Cited by 22 · see citing works

Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography–Tandem Mass Spectrometry

Amrani, M. E., Bosman, S. M., Egas, A. C., Hack, C. E., Huitema, A. D. R., & van Maarseveen, E. M. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000633 · Cited by 21 · see citing works

Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis

Guo, H., Li, L., Liu, B., Lu, P., Cao, Z., Ji, X., Li, L., Ouyang, G., Nie, Z., Lü, A., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110655 · Cited by 18 · see citing works

Protective effects of Clematichinenoside AR against inflammation and cytotoxicity induced by human tumor necrosis factor-α

Xiong, Y., Ma, Y., Kodithuwakku, N. D., Fang, W., Liu, L., Li, F., Hu, Y., & Li, Y. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.04.010 · Cited by 18 · see citing works

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Vi, M., Gaydukova, I. Z., Erdes, S. F., Дубинина, Т. В., Пристром, А. М., Kunder, E. V., Soroka, N., Кastanayan, A. A., Поварова, Т. В., Zhugrova, E. S., et al. (2020) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2020-376-386 · Cited by 18 · see citing works

Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay

Hock, B. D., McKenzie, J. L., Goddard, L., Smith, S. M., McEntyre, C. J., & Keating, P. E. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000553 · Cited by 17 · see citing works

Knowledge, attitude, future expectations and perceived barriers of medical students and physicians regarding pharmacogenomics in Jordan

Alzoubi, A., Kanaan, H., Alhazaimeh, D. A., Gharaibeh, S., Mukattash, T. L., & Kheirallah, K. A. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13658 · Cited by 17 · see citing works

How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?

Upham, J. W., & Jurak, L. M. (2020) · Clinical & Experimental Allergy · doi:10.1111/cea.13694 · Cited by 17 · see citing works

Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track

Ilan, Y. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru0718-276rr · Cited by 16 · see citing works

Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges

Avouac, J., Kay, J., & Choy, E. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152740 · Cited by 18 · see citing works

Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin ( IL )‐17 or IL ‐12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review

Xie, Y., & Liu, Y. (2022) · Clinical and Experimental Dermatology · doi:10.1111/ced.15237 · Cited by 15 · see citing works

Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

Bodio, C., Grossi, C., Pregnolato, F., Favalli, E. G., Biggioggero, M., Marchesoni, A., Murgo, A., Filippini, M., Migliorini, P., Caporali, R. F., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102509 · Cited by 15 · see citing works

The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms

González‐Hernández, A., Marichal‐Cancino, B. A., García-Boll, E., & Villalón, C. M. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200618144637 · Cited by 15 · see citing works

Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits

Mendieta, E. J. L., Salvador‐Martín, S., Marín‐Jiménez, I., Menchen, L. A., López-Cauce, B., López-Fernández, L. A., & Lucendo, A. J. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114003 · Cited by 14 · see citing works

Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor

Bustos, R., Zapata, C., Esteban, E., Casallas, J. C. G., Jauregui, E. A., & Jaimes, D. A. (2018) · Sensors · doi:10.3390/s18030691 · Cited by 13 · see citing works

Biologika und „small molecules“ bei der rheumatoiden Arthritis

Blüml, S. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00766-7 · Cited by 12 · see citing works

Current status of the immunogenicity of enzyme replacement therapy in fabry disease

Gómez-Cerezo, J. F., Fernández-Martín, J., Barba-Romero, M. Á., Sánchez‐Martínez, R., Ameijeiras, Á. H., Camprodón-Gómez, M., Ortolano, S., & Rodriguez, M. L. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03705-4 · Cited by 11 · see citing works

Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study

Esatoğlu, S. N., Akkoc-Mustafayev, F. N., Özgüler, Y., Ozbakir, F., Nohut, O. K., Cevirgen, D., Hamuryudan, V., Hatemı, İ., Çelık, A. F., Yazıcı, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618973 · Cited by 10 · see citing works

Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview

Song, Y., Nam, S. W., Suh, C., Choe, J., & Yoo, D. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2270407 · Cited by 10 · see citing works

Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients

Magill, L., Adriani, M., Berthou, V., Chen, K., Gleizes, A., Hacein‐Bey‐Abina, S., Hincelin-Méry, A., Xavier Mariette, A., Pallardy, M. J., Spindeldreher, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02865 · Cited by 10 · see citing works

Immunogenicity risk mitigation of therapeutic proteins with translational immunogenicity, analytical characterization, and regulatory insight

Shadbar, S., Balu-Iyer, S. V., Auclair, J. R., & Dadon, D. B. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103870 · Cited by 9 · see citing works

NHWD-1062 ameliorates inflammation and proliferation by the RIPK1/NF-κB/TLR1 axis in Psoriatic Keratinocytes

Guo, Y., Jin, L., Dong, L., Zhang, M., Kuang, Y., Chen, X., Zhu, W., & Yin, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114638 · Cited by 8 · see citing works

Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach

Brekkan, A., Lledó‐García, R., Lacroix, B. D., Jönsson, S., Karlsson, M. O., & Plan, E. L. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09890-8 · Cited by 8 · see citing works

Anti‐ TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

Baut, G. L., Peyrin‐Biroulet, L., Bouguen, G., Gornet, J., Stéfanescu, C., Amiot, A., Laharie, D., Altwegg, R., Fuméry, M., Trang, C., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14946 · Cited by 8 · see citing works

Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial

Watanabe, R., Tanaka, Y., Takeuchi, T., Okamoto, S., Kyuuma, M., Matsumoto, R., Nakayama, Y., Katsushima, M., & Hashimoto, M. (2025) · Lara D. Veeken · doi:10.1093/rheumatology/keaf171 · Cited by 7 · see citing works

Novel TNF-α-targeting mRNA therapy for sustained psoriasis treatment and relapse prevention by suppressing IL-15-TRM signaling

Li, X., Shao, X., Li, X., Chen, Q., Zang, Y., Wang, J., Yang, Y., Qiang, L., Lin, A., & He, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114218 · Cited by 8 · see citing works

Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?

Shipa, M. R. A., Cicco, M. D., Balogh, E., Nitu, N. A., Mainuddin, M., Bhadauria, N., Mukerjee, D., & Roussou, E. (2022) · Modern Rheumatology · doi:10.1093/mr/roac086 · Cited by 7 · see citing works

Hepatorenal pathologies in TNF-transgenic mouse model of rheumatoid arthritis are alleviated by anti-TNF treatment

Li, X., Wang, Y., Chen, Z., Ruan, M., Yang, C., Zhou, M., Li, N., Xing, L., Xu, H., Yang, L., et al. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03178-5 · Cited by 7 · see citing works

Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum

Hock, B. D., Smith, S. M., McEntyre, C. J., McKenzie, J. L., Sies, C. W., & Keating, P. E. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.112672 · Cited by 7 · see citing works

Unlocking the antiviral potential of rosmarinic acid against chikungunya virus via IL-17 signaling pathway

Liao, X., Xin, J., Yu, Z., Yan, W., Li, C., Cao, L., Zhang, H., & Wang, W. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1396279 · Cited by 6 · see citing works

Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering

Pimentel, C. Q., Ribeiro, A. C. D. M., Shimabuco, A. Y., Sampaio-Barros, P. D., de Moraes, J. C. B., Goldenstein‐Schainberg, C., Gonçalves, C. R., Leon, E. P., Kupa, L. D. V. K., Pasoto, S. G., et al. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42923 · Cited by 6 · see citing works

Influence of Immunogenicity of Adalimumab on Prognosis of Patients with Non-Infectious-Uveitis: A Systematic Review

Nogueras, V. S. F. , Hidalgoa, L. M., Rodríguez, E. J., García‐Basterra, I., de Zea, P. R., & Alba‐Linero, C. (2025) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2025.2486371 · Cited by 5 · see citing works

Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF inhibitor therapy in rheumatic disease: A systematic review and meta-analysis

Dong, W., Hu, X., Wu, C., Wang, G., Fang, Y., Shi, L., & Nie, X. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152302 · Cited by 5 · see citing works

Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders

Murakami, K., & Mimori, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1423-18 · Cited by 5 · see citing works

Puerarin exerts an inhibitory effect on inflammatory infiltration in the cardiac tissue of EAM mice by regulation of the TNF-α/CCL2/CCR2 signal pathway

Liu, M., Li, L., Tong, H., Kong, X., Wang, L., Jia, X., Wang, T., Yu, D., Li, Y., & Wang, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114721 · Cited by 4 · see citing works

Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review

Barešić, M., Smiljanić, L., Anić, B., & Mayer, M. (2022) · Rheumatology International · doi:10.1007/s00296-021-05065-1 · Cited by 4 · see citing works

Repurposing a detrimental antibody epitope as targeted therapeutics for sepsis and rheumatoid arthritis

Chen, W.-Q., Lou, L., Qiang, X.-L., Zhu, S., Li, J.-H., Chen, S.-J., Xiong, B. V., Yang, H., Wang, P., Tracey, K. J., et al. (2026) · Military Medical Research · doi:10.1186/s40779-026-00686-8 · Cited by 3 · see citing works

A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults

Wang, Q., Xie, X., Su, F., Wang, J., Chen, S., Wang, Q., Jiang, D., Wang, Y., Zhang, T., Liu, C., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105807 · Cited by 3 · see citing works

Effect of Anti-TNFα Therapy by Infliximab against Pancreatic Tissue Damage in Severe Acute Necrotizing Pancreatitis.

Alekhin, S. A., Firsova, T. I., Nazarenko, D. P., Bezhina, E. N., & Druzhikin, L. V. (2021) · PubMed Central · doi:10.22092/ari.2021.355845.1726 · Cited by 2 · see citing works

Seasoning to Perfection: How to Optimize Anti-TNF Therapy

Rosenbaum, J. T., & Friedman, M. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1964032 · Cited by 1 · see citing works

Personalized Medicine in Autoimmunity

Meroni, P. L., & Gualtierotti, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814307-0.00057-8

Avaliação da atividade anti-inflamatória de derivados de imidazopiridinas (IMPs) pela inibição de TNF-alfa

Assumpção, J. A. F. (2018) · doi:10.26512/2018.02.t.39585

New Trends in Developing Therapeutic Proteins by Synthetic Cells on Diseased Tissues

Ajaykumar, C., Ravinder, D., Akbar, P., & Chembuli, V. S. S. N. A. (2023) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-6684-6577-6.ch008

Odontologiske aspekter ved behandling med biologisk medicin

Pedersen, A. M. L., & Locht, H. (2024) · Aktuel nordisk odontologi · doi:10.18261/ano.49.1.11

A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial

Jia, D., Wang, H., Jiang, W., Shen, Y., Guo, J., Zhao, D., Zhang, M., Meng, H., Xue, H., Song, Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1676908

Statistical Methodology for Qualification of a Non-Clinical Risk Assessment Peptide:T Cell Proliferation Assay to Support Decision MakingPreprint

Tourdot, S., You, Z., Ciarla, A., Hindin, R., Keenan, B., Calderini, J., den Broek, S. V., Lepsy, C. S., Hickling, T. P., & Steeno, G. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.03.729894

Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment

Kalden, J. R., & Schulze‐Koops, H. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.187 · Cited by 190 · see citing works

Measurement of anti-drug antibodies to biologic drugs: Fig. 1

Felis‐Giemza, A., & Moots, R. J. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev279 · Cited by 15 · see citing works

What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?

Mehta, P., & Manson, J. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00589 · Cited by 40 · see citing works

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Xavier Mariette, A., & Marcelli, C. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356 · see citing works

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

van Schouwenburg, P. A., Rispens, T., & Wolbink, G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 441 · see citing works